[HTML][HTML] Pathophysiological role of guanylate-binding proteins in gastrointestinal diseases

N Britzen-Laurent, C Herrmann… - World journal of …, 2016 - ncbi.nlm.nih.gov
N Britzen-Laurent, C Herrmann, E Naschberger, RS Croner, M Stürzl
World journal of gastroenterology, 2016ncbi.nlm.nih.gov
Guanylate-binding proteins (GBPs) are interferon-stimulated factors involved in the defense
against cellular pathogens and inflammation. These proteins, particularly GBP-1, the most
prominent member of the family, have been established as reliable markers of interferon-γ-
activated cells in various diseases, including colorectal carcinoma (CRC) and inflammatory
bowel diseases (IBDs). In CRC, GBP-1 expression is associated with a Th1-dominated
angiostatic micromilieu and is correlated with a better outcome. Inhibition of tumor growth by …
Abstract
Guanylate-binding proteins (GBPs) are interferon-stimulated factors involved in the defense against cellular pathogens and inflammation. These proteins, particularly GBP-1, the most prominent member of the family, have been established as reliable markers of interferon-γ-activated cells in various diseases, including colorectal carcinoma (CRC) and inflammatory bowel diseases (IBDs). In CRC, GBP-1 expression is associated with a Th1-dominated angiostatic micromilieu and is correlated with a better outcome. Inhibition of tumor growth by GBP-1 is the result of its strong anti-angiogenic activity as well as its direct anti-tumorigenic effect on tumor cells. In IBD, GBP-1 mediates the anti-proliferative effects of interferon-γ on intestinal epithelial cells. In addition, it plays a protective role on the mucosa by preventing cell apoptosis, by inhibiting angiogenesis and by regulating the T-cell receptor signaling. These functions rely to a large extent on the ability of GBP-1 to interact with and remodel the actin cytoskeleton.
ncbi.nlm.nih.gov